Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Sarmiento

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Haematologica|September 28, 2019
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancerCinzia Giaccherini, Marina Marchetti, Giovanna Masci, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Haematologica|September 28, 2019
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancerCinzia Giaccherini, Marina Marchetti, Giovanna Masci, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2023
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohortCristina Verzeroli, Cinzia Giaccherini, Laura Russo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
Cancers|September 28, 2023
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer PatientsPatricia Gomez-Rosas, Cinzia Giaccherini, Laura Russo, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 3